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Introduction Depression is a common mental health 
disorder during pregnancy, with important consequences 
for mothers and their children. Despite this, it goes 
undiagnosed and untreated in many women attending 
antenatal care. Smartphones could help support 
the prompt identification of antenatal depression in 
this setting. In addition, these devices enable the 
implementation of ecological momentary assessment 
techniques, which could be used to assess how mood 
is experienced during pregnancy. With this study, we 
will assess the feasibility of using a bespoke mobile 
application (app) running on participants’ own handsets for 
the longitudinal (6 months) monitoring of antenatal mood 
and screening of depression.
Methods and analysis We will use a randomised 
controlled study design to compare two types of 
assessment strategies: retrospective + momentary 
(consisting of the Edinburgh Postnatal Depression Scale 
plus five momentary and two contextual questions), 
and retrospective (consisting of the Edinburgh Postnatal 
Depression Scale only). We will assess the impact 
that these strategies have on participant adherence 
to a prespecified sampling protocol, dropout rates 
and timeliness of data completion. We will evaluate 
differences in acceptance of the technology through a 
short quantitative survey and open-ended questions. 
We will also assess the potential effect that momentary 
assessments could have on retrospective data. We will 
attempt to identify any patterns in app usage through the 
analysis of log data.
Ethics and dissemination This study has been reviewed 
and approved by the National Research Ethics Service 
Committee South East Coast—Surrey on 15 April 2016 
as a notice of substantial amendment to the original 
submission (9 July 2015) under the Research Ethics 
Committee (REC) reference 15/LO/0977. This study is 
being sponsored by Imperial College London under the 
reference number 15IC2687 and has been included in 
the UK Clinical Research Network Study Portfolio under 
the Central Portfolio Management System number 19280. 
The findings of this study will be disseminated through 
academic peer-reviewed publications, poster presentations 
and abstracts at academic and professional conferences, 
discussion with peers, and social media. The findings of 
this study will also inform the PhD theses of JSMB and KD.
InTroducTIon
Antenatal depression is one of the most 
common mental health disorders during 
pregnancy.1–4 Point prevalence estimates vary 
between 7% and 12% (depending on the 
trimester), and period prevalence estimates 
suggest that as many as 12.7% of pregnant 
women could experience an episode of major 
depression.3 5 Moreover, antenatal depres-
sion is associated with long-term adverse 
health outcomes in both mothers and their 
offspring. Pregnant women suffering from 
Strengths and limitations of this study
 ► This study will explore (1) the role of mobile 
technology as a medium to address some of the 
practical barriers preventing depression screening 
in antenatal settings; (2) how mood and depression 
are experienced throughout pregnancy (using 
momentary, experiential and ecological data) and 
(3) two critical success factors for the successful 
deployment of mobile technology in pregnancy: user 
engagement and adherence to a proposed sampling 
protocol.
 ► This study will provide baseline information 
regarding the appropriateness of a sampling protocol 
(in terms of its duration, intensity and frequency) for 
the monitoring of mood and screening of depression 
during the antenatal period.
 ► The technology used in this study has been 
specifically designed and developed to fit within the 
clinical context and the local care pathways in which 
it will be deployed.
 ► This study focuses on mood and antenatal 
depression. It does not consider other common 
mental health disorders that occur during pregnancy, 
or the presence of potential triggers or risk factors 
(eg, domestic violence).
 ► The mood-related momentary questions used in this 
study have not been validated..
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depression are more likely to engage in unhealthy prac-
tices (including poor diet, substance abuse and failure 
to enrol in prenatal care), and are at increased risk of 
self-harm (or suicide) and postpartum depression.1 6 
Antenatal depression can also affect fetal development, 
and has been identified as an independent risk factor for 
a child’s behavioural, cognitive and emotional develop-
ment (including through adolescence).1 7–9
Research indicates that there is no difference in the 
prevalence or incidence of depression between preg-
nant and non-pregnant women.10 However, the rate of 
diagnosis and treatment might be lower in pregnant 
women.10 Approximately three-quarters of pregnant 
women meeting the diagnostic criteria for depression 
(and anxiety) are not identified, and only 1 in 10 of those 
who require further treatment is able to access it.11 Some 
of the barriers to the prompt diagnosis of this disorder 
include difficulties in differentiating depressive symp-
toms from the expected mood and somatic changes of 
pregnancy, stigma, lack of reassurance that mental health-
care is a normal part of antenatal care, characteristics of 
healthcare providers, configuration of health services, 
insufficient consultation time and the cost-effectiveness 
of screening practices.10–12
As with other mental health conditions,13–16 smart-
phones could help address some of the practical barriers 
and facilitate the screening and monitoring of depression 
throughout the antenatal period. The computational 
capabilities of these devices allow them to implement vali-
dated screening scales (usually retrospective self-reports) 
at any frequency and for any duration. Smartphones are 
also able to support the implementation of techniques 
for the collection of momentary, experiential and ecolog-
ically valid data. Being collected in real time, momentary 
data are less susceptible to many of the biases common 
to retrospective scales (eg, recall bias) and are more 
sensitive to fluctuations over time.17–19 The networking 
capabilities and wide availability (approximately 71% of 
UK adults)20 21 of smartphones, and the software develop-
ment and distribution framework of mobile applications 
(apps), could help practitioners to circumvent some of 
the practical challenges associated with screening and 
clinical monitoring, and reduce the costs associated with 
data handling and management.
Altogether, these characteristics could contribute to 
making the screening and monitoring of antenatal depres-
sion more cost-effective: an initial resource-intensive app 
development phase would be followed by a relatively 
low-cost, large-scale distribution of the app onto patients 
who own smartphones. Thereafter, regular depression 
assessments could take place remotely, at anytime and 
anywhere (further comprehensive clinical assessments 
and the provision of treatment being dependent on local 
referral and care pathways). Nonetheless, the feasibility of 
using smartphones for this purpose needs to be explored.
In this area of research, a key factor is the patient’s will-
ingness to run screening or clinical monitoring apps on 
their personal handsets.16 This could influence patient 
compliance with clinician-led data gathering (sampling) 
protocols, and thus affect data completeness. The latter 
refers to the minimum amount of information required 
by clinicians to inform their decisions, and is an important 
data quality dimension in healthcare.21 Data complete-
ness is also susceptible to the burden that the intensity of 
sampling protocols (both in terms of frequency and dura-
tion) can place on patients, as well as on the value that 
patients might derive from the data collected. Moreover, 
the impact that adding momentary assessments can have 
on retrospective data also needs to be explored, as this 
could lead to more efficient diagnostic and therapeutic 
decisions.
This study is part of a project aimed at understanding 
the role of mobile technology for the screening and 
assessment of antenatal depression and psychological 
well-being in the context of antenatal care pathways in 
the National Health Service (NHS) in the UK. A previous 
feasibility study assessed the feasibility of using iPads in 
the waiting area of antenatal clinics for implementing 
the National Institute for Health and Care Excellence 
(NICE) recommendations for the recognition of depres-
sion.22 The present study will explore the feasibility of 
using a bespoke app to support the longitudinal and 
remote assessment of mood and depression screening 
throughout the antenatal period. We will evaluate issues 
of patient acceptance (namely, adherence to sampling 
protocols and dropout rates) by comparing two 6-month 
sampling protocols requiring either (1) monthly retro-




We will assess the feasibility of using a bespoke mobile 
application, called BrightSelf, running on participants’ 
own smartphones to assess and monitor depression and 
mood during the antenatal period through a combination 
of retrospective assessments and ecological momentary 
assessments (EMA).
We will use a parallel, randomised controlled study 
design to assign our participants to one of two types of 
assessment strategies:
1. Retrospective plus momentary assessment: requiring 
the completion of (1) the Edinburgh Postnatal 
Depression Scale (EPDS), (2) five momentary 
questions (assessing a participant’s mood, sleep, 
worry, enjoyment and energy levels), and (3) two 
contextual questions once a month for 6 months
2. Retrospective assessment: requiring the completion 
of the EPDS once a month for 6 months.
sample selection and recruitment
We will select our sample of participants from women 
attending antenatal clinics in general practices, commu-
nity services and secondary care NHS centres in England 
during their first 14 weeks of pregnancy. We have chosen 
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this limit to ensure that most assessments will occur 
during pregnancy.
On the day of their antenatal appointment, each poten-
tial participant will be approached by a clinical studies 
officer (CSO) or a research midwife with appropriate 
good clinical practice training, and will be provided with 
a participant information sheet. Potential participants 
expressing their interest in taking part in this study will 
be assessed against our inclusion and exclusion criteria 
(table 1).
Potential participants meeting our inclusion criteria 
will have all the study details explained to them, and will 
be given the opportunity to ask as many questions about 
the study as they need. Potential participants will have a 
minimum of 24 hours to decide on participation; refusal 
to take part in this study will not have an impact on their 
legal rights, medical care or their relationship with care 
providers.
We will obtain written informed consent from those 
potential participants who, after receiving all the relevant 
study information and having all their questions answered 
to their satisfaction, still wish to take part in this study.
After obtaining consent, participants will be asked 
to self-complete a baseline assessment using a tablet 
computer. This assessment will consist of a (1) sociode-
mographic survey, (2) the Whooley questions and (3) the 
EPDS (see online supplementary appendix 1). The last 
two instruments are recommended by the NICE to screen 
for depression during pregnancy.23 Subsequently, the 
CSO or research midwife will guide participants through 
the process of downloading (from either the Apple 
AppStore or Google Play Store) and installing BrightSelf 
onto their own handsets. To this end, they will be able to 
use a recruiter booklet provided by the central research 
team (see online supplementary appendix 2). In order 
to activate the app, participants will need to enter a nine-
digit activation code, which will also be provided by the 
central research team.
Interventions to be measured
Surveys
Non-validated, sociodemographic survey
We will administer an 11-question survey to collect infor-
mation about participants’ age group, ethnic background, 
marital status, employment status, level of education, 
smartphone and tablet computer ownership, obstetric 
history, and personal history of depression.
Whooley questions
The Whooley questions were developed as a case-
finding instrument for depression in primary care.24 
This two-question instrument assesses depressed mood 
and anhedonia that have been present during the past 
month. Respondents are required to answer Yes or No to 
each question.
Edinburgh Postnatal Depression Scale
The EPDS is a 10-item self-administered survey that was 
originally developed to screen for postpartum depres-
sion.25 Since then it has been validated for use in the 
perinatal period and for use in community and clinical 
settings. This instrument assesses feelings of guilt, sleep 
disturbance, anhedonia and suicidal ideation that have 
been present during the past 7 days. Each question is 
scored on a 4-point scale ranging from 0 to 3 points. An 
overall score is generated from the sum of these responses.
Although there is variability in the diagnostic accuracy 
of different EPDS scores, the following thresholds are 
commonly used: 10 points for possible depression, 13 for 
probable depression and 15 for antenatal depression.26 
In addition, special attention should be paid to item 10, 
as it deals with suicidal thoughts. Based on these scores, 
a clinician would be prompted to refer a woman to a 
mental health professional.
The EPDS is a valid and reliable tool for identifying 
women who are at risk of depression, both during preg-
nancy and postpartum. This instrument is also sensitive 
to changes in the severity of depression over time.25 The 
EPDS can be reproduced without further permission 
provided that the original source of the scale is cited in 
each reproduced copy.
Table 1 Participant inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Women who are 18 years old or older Current diagnosis of depression or other mood disorder 
made by a health professional
Up to 14 weeks pregnant (assessed through a dating ultrasound 
scan)
Currently receiving treatment for depression or other mood 
disorder (whether it is talking therapies or pharmacological 
treatment)
Any parity Recent personal history of depression or other mood disorder 
in the past 12 months
Attending antenatal clinics in participating National Health 
Service sites
Not comfortable reading and writing in English
Own smartphone (either an iPhone or any type of Android 
handset)
Not owning a smartphone, or owning an incompatible 
handset (ie, Windows Phone, Blackberry or Linux)
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Non-validated, momentary mood questions
We will administer five momentary questions to assess 
participants’ mood, sleep, worry, enjoyment and energy 
(see online supplementary appendix 3). These questions 
are based on the work of a research fellow at the Collab-
oration for Leadership and Applied Health Research 
and Care for the East of England.27 Each question will 
be mapped onto 5-point pictorial scales, ranging from 1 
(low) to 5 points (high). For the purpose of this feasibility 
study, we will not perform any overall score calculation or 
attempt any validation of these questions.
Non-validated, contextual questions
Two contextual questions will complement the momen-
tary mood questions (see online supplementary appendix 
3). They will assess (1) participants’ location and (2) the 
activity in which they were engaged at the time they were 
required to complete the five momentary mood ques-
tions.
Non-validated, poststudy acceptance survey
We will administer 13 questions (to participants 
completing retrospective assessments) or 14 questions 
(to participants completing retrospective plus momen-
tary assessments) at the end of the 6-month participation 
period (see online supplementary appendix 4). The 
purpose of these questions is to assess the acceptability to 
participants of BrightSelf in the context of their antenatal 
care, and to gather information about their experience 
of using it. These questions were derived from the Useful-
ness, Satisfaction and Ease of Use (USE) questionnaire28 
(which focuses on usability) and also include a question 
concerning the desire to continue use (as used to assess 
engagement29), as well as questions regarding the expe-
rience of use and self-report. We will administer them as 
a web survey through Snap survey software30 by sending 
participants a link via e-mail or short messaging service 
(SMS).
Mobile system
BrightSelf is a mobile system for the collection of 
self-reports, both retrospective and momentary, during 
pregnancy. This system is not a diagnostic tool and is not 
intended to replace the role of clinicians within antenatal 
or mental healthcare pathways.
This system elicits retrospective reports through the 
EPDS, and momentary reports according to the five 
constructs of mood, sleep, worry, enjoyment and energy. 
In addition, the system can suggest brief activities that 
users can perform to lift their mood, additional informa-
tion about the system and the feasibility study, additional 
resources should they need immediate help, and a 
visualisation of past self-reports. We will emphasise to 
the participants that BrightSelf is not a clinical tool, and 
that if they feel they need immediate help at any point 
during the study they should contact their general prac-
titioners.
BrightSelf consists of mobile applications for Android 
and iOS operating systems, a backend for the storage 
and management of data, and a website that supports the 
monitoring of data.
A complete description of BrightSelf is the aim of 
another publication. Here we describe the two features 
that are most relevant to this feasibility study, namely the 
collection of retrospective and momentary self-reports.
Check Back
This feature will enable the administration of the EPDS. 
It consists of two introductory screens informing partic-
ipants of the retrospective nature of this scale and its 
intended applications. These screens will be followed 
by the 10 EPDS questions, presented one question per 
screen, using radio buttons to capture participants’ 
responses (figure 1).
Check In
This feature will enable the administration of the five 
momentary questions and the two contextual questions. 
The first five questions will be presented using a 5-point 
pictorial scale with temporary supporting text (see 
figure 2 for an example). The last two questions will use 
radio buttons to capture participants’ responses.
Retrospective versus momentary assessments
Participants will be asked to complete monthly assessments 
at irregular intervals for 6 months. Whenever an assessment 
is due (as per the sampling protocol), a notification will be 
displayed on a participant’s handset. There will be two types 
of notifications: one for the Check Back feature and one for 
the Check In feature of BrightSelf. The visual appearance of 
the notifications will depend on the operating system and 
on the model of the participant’s handset. The text of the 
Figure 1 BrightSelf—Check Back (screenshot).
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notifications, however, will remain constant across partici-
pants for each type of notification.
Participants will be able to respond (and thus complete 
the corresponding assessments) or to dismiss the noti-
fications. In addition, participants will be able to leave 
notifications unanswered. If participants do not complete 
an assessment in response to a notification, they will not 
receive reminders or follow-up notifications. In these 
instances, the non-response will be recorded in our data-
base and will be coded as such for the purposes of our 
data analysis.
Outside assessment periods, participants will be able to 
use BrightSelf in any way they find convenient and there 
will be no restrictions on the number of assessments they 
can complete on a single day. However, we will be able to 
distinguish between assessments completed in response 
to a notification and those completed spontaneously. At 
baseline, participants will be randomly allocated to one 
of two types of assessment strategies:
Retrospective plus momentary assessments
In this experimental manipulation, participants will be 
asked to complete a combination of retrospective assess-
ments and momentary assessments. A retrospective 
assessment will be defined as a single administration of the 
EPDS. A momentary assessment will be defined as the five 
momentary questions plus the two contextual questions.
Participants will be required to complete assessments 
for a total of 6 months, and each assessment period will 
consist of six consecutive days. The 6-month participa-
tion period will be calculated from the day on which 
the app is activated (ie, when participants enter their 
activation code and activate their account), and it will 
be divided into six intervals. All participants will receive 
the first notification 2 days after activating BrightSelf 
(ie, first assessment), while the use of the app is fresh 
within their minds and to give an idea of what to expect 
during the study. Subsequent assessment periods will be 
a random selection of six consecutive days within the 
21–35 days following the end of the previous assessment 
period (in order to avoid 12 days of continuous assess-
ments).
The assessment period will be structured as follows:
 ► Day 1: one retrospective assessment at any random 
time between 17:00 and 21:00
 ► Days 2–5: three momentary assessments per day, 
displayed at random times within each of the 
following intervals: 09:00–12:00, 13:00–16:00 and 
17:00–20:00
 ► Day 6: one retrospective assessment at any random 
time between 17:00 and 21:00.
At the end of the 6-month period, participants will be 
sent a link via SMS or by e-mail to complete the non-vali-
dated, poststudy acceptance survey.
Retrospective assessments
In this experimental manipulation, participants will 
be asked to complete retrospective assessments only. A 
retrospective assessment will be defined as a single admin-
istration of the EPDS.
Participants will be required to complete assessments 
for a total of 6 months, and each assessment period will 
consist of 1 day. The 6-month participation period will be 
calculated from the day on which the app is activated (ie, 
when participants enter their activation code and activate 
their account), and it will be divided into six intervals. 
Again, all participants will receive the first notification 
2 days after activating BrightSelf (ie, first assessment). 
Subsequent assessments will take place on a random day 
within the 21–35 days following the end of the previous 
assessment period (in order to avoid two consecutive 
EPDS assessments).
On each assessment day, participants will receive a noti-
fication to complete the EPDS at a random time between 
17:00 and 21:00.
At the end of the 6-month period, participants will be 
sent a link via SMS or by e-mail to complete the non-val-
idated, poststudy acceptance survey (see figure 3 for an 
illustration of both sampling protocols).
Duty of care
Regardless of participants’ allocation, the central 
research team will be alerted if any of a series of 
prespecified conditions are met (table 2). These alerts 
will be colour-coded according to their severity level. In 
order to determine the severity level, we have chosen 
commonly used EPDS scoring thresholds (ie, 10–12 
points for possible depression, and 13 points or more 
for probable depression). We acknowledge the limita-
tions of this approach as the diagnostic accuracy of the 
EPDS can vary depending on the setting and the popu-
lation in which it is administered.
Figure 2 BrightSelf—Check In (screenshot).
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Before starting the study, the central research team 
will agree on a list of designated contacts with the rele-
vant clinical care teams. These contacts will include 
clinicians who are available during normal working 
hours, as well as those on duty outside working hours 
(including weekends and bank holidays). If a red or 
orange alert is generated, the study coordinator will 
contact the designated member of the clinical care 
team by phone and e-mail within 24 hours of receiving 
the alert. The clinical care team will then follow up 
these alerts directly with the participants.
randomisation
We will use block randomisation procedures (with blocks 
of four) to allocate participants to one of the two exper-
imental arms. Random numbers will be generated using 
Stata V.14.31 Each consecutive number will be embedded 
within the nine-digit activation codes that will be distrib-
uted to each participating NHS site. The full activation 
codes will be generated in the same order in which the 
random numbers were generated. Each NHS site will 
receive a list of activation codes on a first-come-first-
served basis. Members of the local research teams will 
not be informed of the random sequence generation 
and will not be able to identify which number deter-
mines participant allocation. They will be required to 
use activation codes sequentially, as participants are 
recruited. Activation codes referring to the retrospective 
plus momentary assessment condition will activate a version 
of BrightSelf in which both the Check Back and the Check 
In features are active. Activation codes referring to the 
retrospective assessment condition will activate a version of 
BrightSelf in which only the Check Back feature is active.
outcomes
Adherence to sampling protocols
We will calculate the number of participants who complete 
100% of the expected assessments (as per the study 
protocol) as a proportion of the total number of partici-
pants who were randomised into the study. We will subdivide 
this outcome by using the total number of participants who 
complete the 6-month participation period as the denom-
inator.
Figure 3 Sampling protocols for the retrospective plus momentary assessments and for the retrospective 
assessments. EPDS, Edinburgh Postnatal Depression Scale.
Table 2 Criteria for an alert to be sent to the research team
Type of alert Criteria
Yellow (Mild) Completing more than one EPDS assessment on the same day, 
with an overall EPDS score of 9 points or less and a score of 0 on 
question 10 of the EPDS
Orange (Moderate) Overall EPDS score between 10 and 12 points, with a score of 0 on 
question 10 of the EPDS
Red (Severe) Overall EPDS score of 13 points or more, and
1 or more points on question 10 of the EPDS, regardless of the 
overall EPDS score
EPDS, Edinburgh Postnatal Depression Scale. 
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Dropout rates
We will calculate the number of participants who complete 
the 6-month participation period as a proportion of the 
total number of participants who were randomised into the 
study.
Usage patterns
We will assess participants’ usage pattern of BrightSelf 
by analysing log data (additional variables capturing app 
usage). These will include the number of additional volun-
tary self-reports, time spent using the app, number of 
interactions with other sections of the app, time taken to 
complete the self-assessments and other ancillary usage data.
Acceptance
We will calculate participants’ ratings and responses 
to the poststudy acceptance survey. In addition, we will 
conduct thematic analysis of participants’ answers to the 
open-ended questions of this survey using  Atlas. ti 8.32
Timeliness of data completion
We will calculate the number of assessments that were 
completed in response to a notification as a proportion of 
the total number of expected assessments. We will subdi-
vide this outcome by using the total number of completed 
assessments as the denominator. We will consider that an 
assessment has been completed in response to a notifica-
tion if it takes place within the interval corresponding to 
that notification (ie, before the next notification is deliv-
ered). This broad interval may raise concerns regarding 
the ecological validity of the report, which we will explore 
in our statistical analysis.
sample size calculations
We have chosen to relate the proposed sample size to the 
95% CI for the adherence rate, as recommended by the 
Research Design Service in London. Therefore, we would 
need 96 participants in each arm with a 95% confidence 
level and a CI of 10. This translates into a total sample of 
192 (ie, 96 participants in each experimental group). For 
this reason, we will aim to recruit at least 250 participants 
to account for dropouts and potential miscarriages.
data analysis plan
Descriptive statistics
We will report the number of potential participants who 
were eligible and refused to take part in the study. Where 
possible, we will report the reasons for refusing to partici-
pate.
For each experimental group, we will report the 
following information:
 ► Demographic characteristics (as captured by the 
non-validated, sociodemographic survey)
 ► Proportion of participants answering Yes to any of the 
Whooley questions during the baseline assessment
 ► Proportion of participants scoring at each interval 
of the EPDS: between 0 and 9 points, between 10 
and 12 points, and 13 points or above during the 
baseline assessment
 ► Proportion of participants scoring 1 or more points 
on question 10 of the EPDS during the baseline 
assessment.
Inferential statistics
We will compare the retrospective and momentary assessment 
and the retrospective assessment experimental groups for 
differences in adherence rates, dropout rates and timeli-
ness of data completion. For this we will use a t-test or the 
non-parametric equivalent.
We will compare acceptance between the two exper-
imental manipulations by assessing differences in 
participants’ rankings to those questions on a 7-point 
Likert scale of the poststudy acceptance survey. We will 
also conduct a thematic analysis of the open-ended ques-
tions of this survey.
In relation to the momentary assessments, we will 
examine the distribution of delays between the time of 
notification and time of report in order to assess the 
effect of this delay on the ecological validity of reports.
We will analyse usage patterns through regression 
modelling of log data. We will analyse participants’ 
momentary and retrospective assessments through time-
based analyses or multilevel modelling.33 34 We will attempt 
to compare if the momentary assessments had any effect 
on the retrospective assessments by comparing the EPDS 
responses given on day 1 to those given on day 6.
Timeline
We expect participant recruitment to start in January 
2017, and the last follow-up to take place in August/
September 2017 (assuming a recruitment period of 2 
months and a half).
conclusIon
This study addresses an important area of unmet clinical 
need, with direct and indirect consequences for mothers, 
children, their families, health systems and society. This 
study will contribute to the growing body of evidence 
concerning the role of mobile technologies for the 
support of mental health. Similarly, it will generate base-
line information concerning the acceptability of an EMA 
sampling protocol (in term of its duration, frequency and 
intensity) to women attending antenatal care. This study 
will also evaluate participant engagement with the tech-
nology and their adherence to a prespecified sampling 
protocol, both of which influence the completeness of 
the data needed by clinicians to inform their decisions. 
In addition, this study will identify some of the implemen-
tation issues that might arise when we attempt to deploy 
mobile technologies in clinical settings, which could 
affect their successful adoption.
In this work, we have maintained a focus on antenatal 
depression. Mental health during pregnancy, however, is 
more complex. Disorders such as anxiety and post-trau-
matic stress disorder are also among the most common 
disorders during this period. Moreover, pregnant women 
who are exposed to certain risk factors or triggers (eg, 
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domestic violence, social isolation, minority groups and 
low income) are at increased risk of suffering from any 
of these mental health problems. Although we have not 
been able to focus on all these issues, we believe that the 
findings from this feasibility study will produce important 
lessons that could enable us to design and develop similar 
technologies and appropriate strategies. We aim to recruit 
participants from diverse backgrounds, and across multiple 
settings and geographical areas within England, and to 
focus on how such technologies can be embedded within 
existing antenatal care pathways, in order to support the 
existing patient–midwife relationship.
The findings from this and from a previous feasibility 
study21 will inform a larger trial evaluating the integration 
of mobile technologies into routine antenatal pathways, 
and their potential impact on clinical outcomes.
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